Dr. Michael Sinha Co-Authors an Article for JAMA
Jessica L. Ciccone
Director of Communications, pro School of Law
jessica.ciccone@slu.edu
(314) 977-7248
Reserved for members of the media.
Professor Michael Sinha, JD, MD recently co-authored an article entitled “” that was published in the Journal of the American Medical Association. The article was written in conjunction with Daniel Aaron, JD, MD and Teneille Brown, JD both of the University of Utah’s S.J. Quinney College of Law.
The article discussed the implications of Judge Kacsmaryk’s opinion in Alliance for Hippocratic Medicine v US Food and Drug Administration, which questioned the FDA’s approval and subsequent Risk Evaluation Management Strategy (REMS) of mifepristone. Dr. Sinha and his co-authors highlighted the risk associated with the decision, such that judges and state attorneys general could further politicize a process meant to be guided by scientific experts. They concluded that “we need enduring solutions that respect rather than flout, the regulatory process” and called for “significant reform to protect the FDA’s scientific process and the very foundations of evidence-based medicine.”
Dr. Sinha joined pro School of Law Center for Health Law Studies faculty in 2022 with an extensive background in law and medicine. He held various research and teaching roles at Harvard Medical School, Northeastern University School of Law, and Loyola University Chicago School of Law. He holds an M.P.H. from Harvard T.H. Chan School of Public Health and an M.D. and J.D. from Southern Illinois University.
Dr. Sinha was also recently published in on drug pricing problems and the roadblocks for more accessible public health medications.